| Code | CSB-RA011661MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Telikibart, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two critical cytokines in type 2 inflammatory responses. Upon ligand binding, IL4R initiates JAK-STAT signaling cascades that promote Th2 cell differentiation, IgE class switching, and the production of inflammatory mediators. Dysregulated IL4R signaling plays a central role in allergic diseases, atopic dermatitis, asthma, and certain fibrotic conditions, making it an important therapeutic target for type 2 inflammation-driven disorders.
Telikibart is a clinical-stage therapeutic antibody designed to block IL4R signaling by preventing both IL-4 and IL-13 from binding to their receptor complexes. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 immune responses, and exploring mechanisms underlying allergic and inflammatory diseases. It supports studies in immunology, dermatology, and respiratory research where IL4R antagonism is of scientific interest.
There are currently no reviews for this product.